Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

Main Content

Collection of Articles on COVID-19 and Movement Disorders

Important information on SARS-CoV-2 Variant
Evidence suggests that the new virus variant spreads much more easily and may lead to a substantial increase of numbers in those countries where it is spreading, as in UK. Caution should be taken as the rapid Antigen test may not detect this variant. Currently the PCR is still efficient and detects the virus, but it needs to be observed further. Further information is included in the following articles:

Articles by Topic

Open AllClose All
  COVID-19 Vaccine

Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson Disease.
Erro R, Buonomo AR, Barone P, Pellecchia MT. Mov Disord. 2021 Aug 9

Slideshow created by MDS SIC Committee

COVID-19 Vaccination for Persons with Parkinson’s Disease: Light at the End of the Tunnel?

Bloem, Bastiaan R.,Trenkwalder, Claudia, Sanchez-Ferro, Alvaroc, Kalia, Lorraine V., Alcalay, Roy, Chiang, Han-Linf, Kang, Un Jungg, Goetz, Christopher, Brundin, Patriki, Papa, Stella M.  Journal of Parkinson's Disease, vol. Pre-press, no. Pre-press, pp. 1-5, 2021

Transient akathisia after the SARS-Cov-2 vaccine.

Salinas MR, Dieppa M. Clin Park Relat Disord. 2021;4:100098. doi: 10.1016/j.prdoa.2021.100098

  Overall Impact of COVID-19 on PD

Outcome of Hospitalized Parkinson's Disease Patients with and without COVID-19.
Parihar R, Ferastraoaru V, Galanopoulou AS, Geyer HL, Kaufman DM. Mov Disord Clin Pract. 2021 May 3:10.1002/mdc3.13231.

The impact of Parkinson's disease on manifestations and outcomes of Covid-19 patients: A systematic review and meta-analysis.
El-Qushayri AE, Ghozy S, Reda A, Kamel AMA, Abbas AS, Dmytriw AA. Rev Med Virol. 2021 Jul 14:e2278. doi: 10.1002/rmv.2278

Covid-19 and Parkinson's disease: an overview.
Cartella SM, Terranova C, Rizzo V, Quartarone A, Girlanda P. J Neurol. 2021 Jul 27:1-7. doi: 10.1007/s00415-021-10721-4.

A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study.
Fabbri M, Leung C, Baille G, Béreau M, Brefel Courbon C, Castelnovo G, Carriere N, Damier P, Defebvre L, Doe de Maindreville A, Fluchere F, Fuzzatti M, Grabli D, Maltete D, Rousseau V, Sommet A A, Thalamas C, Thiriez C, Rascol O, Ory-Magne F. Parkinsonism Relat Disord. 2021 Jul 13;89:128-133.

Physical Activity and Perceived Health in People With Parkinson Disease During the First Wave of Covid-19 Pandemic: A Cross-sectional Study From Sweden.
Leavy B, Hagströmer M, Conradsson DM, Franzén E. J Neurol Phys Ther. 2021 Aug 5.

COVID-19: An Early Review of Its Global Impact and Considerations for Parkinson's Disease Patient Care.
Bhidayasiri R, Virameteekul S, Kim JM, Pal PK, Chung SJ. J Mov Disord. 2020 May;13(2):105-114.

Impact of Prolonged Lockdown due to COVID-19 in Patients with Parkinson's Disease.
Prasad S, Holla VV, Neeraja K, Surisetti BK, Kamble N, Yadav R, Pal PK.Prasad S, et al. Neurol India. 2020 Jul-Aug;68(4):792-795.

The Impact of the COVID-19 Pandemic on Parkinson's Disease: Hidden Sorrows and Emerging Opportunities
Edwards E, Carroll C.

  Pathogenesis

The mechanisms of smell loss after SARS-CoV-2 infection.
Doty RL. Lancet Neurol. 2021 Jul 30:S1474-4422(21)00202-7.

Gut Microbiome Imbalance and Neuroinflammation: Impact of COVID-19 on Parkinson's Disease.
Follmer C.Follmer C. Mov Disord. 2020 Aug 21

Neuropathologic features of four autopsied COVID-19 patients.
Kantonen J, Mahzabin S, Mäyränpää MI, Tynninen O, Paetau A, Andersson N, Sajantila A, Vapalahti O, Carpén O, Kekäläinen E, Kantele A, Myllykangas L.Kantonen J, et al. Brain Pathol. 2020 Aug 6:10.1111/bpa.12889.

Special Collection: COVID-19 Resources

COVID-19 and selective vulnerability to Parkinson's disease.
Pavel A, Murray DK, Stoessl AJ.Pavel A, et al. Lancet Neurol. 2020 Sep;19(9):719.

COVID-19 and Parkinson's Disease: Shared Inflammatory Pathways Under Oxidative Stress
Chaudhry ZL, Klenja D, Janjua N, Cami-Kobeci G, Ahmed BY.

COVID-19 and Parkinson’s disease: Defects in neurogenesis as the potential cause of olfactory system impairments and anosmia
Harini Sri Rethinavel a,1, Sowbarnika Ravichandran a,b,1, Risna Kanjirassery Radhakrishnan a,1, Mahesh Kandasamy a

Is COVID-19 a Perfect Storm for Parkinson's Disease?
Brundin P, Nath A, Beckham JD.

The Possible Protective Role of α-Synuclein Against Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Patients with Parkinson's Disease.
Ait Wahmane S, Achbani A, Ouhaz Z, Elatiqi M, Belmouden A, Nejmeddine M.Ait Wahmane S, et al. Mov Disord. 2020 Jun 9:10.1002/mds.28185.

May Parkinson's disease be a protective factor against CNS involvement by SARS-CoV2?
Spina Tensini F, Spina Tensini T, Franklin GL, Teive HAG.

COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside.

Sulzer D, Antonini A, Leta V, Nordvig A, Smeyne RJ, Goldman JE, Al-Dalahmah O, Zecca L, Sette A, Bubacco L, Meucci O, Moro E, Harms AS, Xu Y, Fahn S, Ray Chaudhuri K. NPJ Parkinsons Dis. 2020 Aug 20;6(1):18.

  PD as Manifestation of Long-COVID

Possible Link between SARS-CoV-2 Infection and Parkinson's Disease: The Role of Toll-Like Receptor 4.
Conte C. Int J Mol Sci. 2021 Jul 1;22(13):7135.

Can COVID-19 accelerate neurodegeneration?
Salari M, Etemadifar M. Clin Case Rep. 2021 Jul 9;9(7):e04433.

Parkinson's Disease in the Era of a Novel Respiratory Virus Pandemic
Otero-Losada M, Kobiec T, Udovin L, Chevalier G, Quarracino C, Menéndez Maissonave C, Bordet S, Capani F, Perez-Lloret S.

Parkinsonism as a Third Wave of the COVID-19 Pandemic?
Beauchamp LC, Finkelstein DI, Bush AI, Evans AH, Barnham KJ.Beauchamp LC, et al. J Parkinsons Dis. 2020 Sep 22.

A Post-COVID-19 Parkinsonism in the Future?
Boika AV. Mov Disord. 2020 May 12:

The Potential Role of SARS-COV-2 in the Pathogenesis of Parkinson's Disease.
Chaná-Cuevas P, Salles-Gándara P, Rojas-Fernandez A, Salinas-Rebolledo C, Milán-Solé A.Chaná-Cuevas P, et al. Front Neurol. 2020 Sep 17;11:1044.

The cognitive consequences of the COVID-19 epidemic: collateral damage?
Karen Ritchie  1   2 , Dennis Chan  3 , Tam Watermeyer  2   4

Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Parkinsonism: Is There Evidence for Concern?
Monje MHG, Martínez-Fernández R.

Can the 2019 Novel Coronavirus Cause Parkinson's Disease?
Achbani A, Sine H, Naciri A, Baba MA, Kharbach A, Bouchriti Y, Nejmeddine M.

Alzheimer's and Parkinson's Diseases Predict Different COVID-19 Outcomes: A UK Biobank Study.

Yu Y, Travaglio M, Popovic R, Leal NS, Martins LM. Geriatrics (Basel). 2021 Jan 26;6(1):10.

  Clinical Course of COVID In PD Patients

COVID-19 manifestations in people with Parkinson's disease: A USA cohort
Yaqian Xu, Matthew Surface, Amanda K Chan, Joshua Halpern, Nora Vanegas-Arroyave, Blair Ford, Megan P Feeney, Kimberly T Kwei, Linn E Katus, Sheng-Han Kuo, Hiral Shah, Cheryl Waters, Linda M Winfield, James C Beck, Serge Przedborski, Stanley Fahn Roy N AlcalayJ Neurol. 2021 Sep 4. doi: 10.1007/s00415-021-10784-3. Online ahead of print.

Integrated multi-omics approach identified molecular mechanism and pathogenetic processes of COVID-19 that affect patient with Parkinson's disorder.
Zhao H, Zhang Q, Chen H, Rezanur Rahman M, Md Faruquee H. Saudi J Biol Sci. 2021 Aug 2.

Outcome of Parkinson's Disease Patients Affected by COVID-19.
Antonini A, Leta V, Teo J, Chaudhuri KR. Mov Disord. 2020 Apr 29:

Predictors of COVID-19 outcome in Parkinson's disease.
Fasano A, Elia AE, Dallocchio C, Canesi M, Alimonti D, Sorbera C, Alonso-Canovas A, Pezzoli G.Fasano A, et al. Parkinsonism Relat Disord. 2020 Aug 13;78:134-137

COVID-19 in Parkinson's disease: what holds the key?
Sainz-Amo R, Baena-Álvarez B, Pareés I, Sánchez-Díez G, Pérez-Torre P, López-Sendón JL, Fanjul-Arbos S, Monreal E, Corral-Corral I, García-Barragán N, Martínez-Castrillo JC, Fasano A, Alonso-Cánovas A

Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study.
Cilia R, Bonvegna S, Straccia G, Nico GA, Elia AE, Romito LM, Devigili G, Cereda E, Eleopra R. Mov Disord. 2020 May 25. doi: 10.1002/mds.28170.

Phenomenology and outcomes of in-patients with Parkinson's disease during COVID-19 pandemic.
Kobylecki C, Jones T, Lim CK, Miller C, Thomson AM.Kobylecki C, et al. Mov Disord. 2020 Jun 24:10.1002/mds.28205.

Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) among Patients at a Movement Disorders Center.
de Marcaida JA, Lahrmann J, Machado D, Bluth L, Dagostine M, Moro-de Casillas M, Bortan E, Kanchana S, Alberts M.de Marcaida JA, et al. Geriatrics (Basel). 2020 Sep 18;5(3):E54. doi: 10.3390/geriatrics5030054.

Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection.
Méndez-Guerrero A, Laespada-García MI, Gómez-Grande A, Ruiz-Ortiz M, Blanco-Palmero VA, Azcarate-Diaz FJ, Rábano-Suárez P, Álvarez-Torres E, de Fuenmayor-Fernández de la Hoz CP, Vega Pérez D, Rodríguez-Montalbán R, Pérez-Rivilla A, Sayas Catalán J, Ramos-González A, González de la Aleja J.

Effects of COVID-19 on Parkinson's Disease Clinical Features: A Community-Based Case-Control Study.
Cilia R, Bonvegna S, Straccia G, Andreasi NG, Elia AE, Romito LM, Devigili G, Cereda E, Eleopra R.Cilia R, et al. Mov Disord. 2020 May 25:10.1002/mds.28170.

Rapid worsening in Parkinson's disease may hide COVID-19 infection.
Hainque E, Grabli D. Parkinsonism Relat Disord. 2020 May 8:S1353-8020(20)30117-6

An educational case series of Parkinson's disease during the COVID-19 pandemic.
Lo Monaco MR, Colacicco G, Marotta J, Bentivoglio AR; GEMELLI AGAINST COVID-19 group.Lo Monaco MR, et al. Rev Neurol (Paris). 2020 Sep 12:S0035-3787(20)30658-5. doi: 10.1016/j.neurol.2020.07.007.

COVID-19 in Parkinson's Disease Patients Living in Lombardy, Italy.
Fasano A, Cereda E, Barichella M, Cassani E, Ferri V, Zecchinelli AL, Pezzoli G. Mov Disord. 2020 Jun 2.

COVID-19: Implications for Sudden Death in Parkinson's Disease.
Fiorini AC, Fonseca MCM, Scorza CA, Finsterer J, Rodrigues AM, de Almeida AG, Scorza FA.Fiorini AC, et al. J Mov Disord. 2020 Aug 31.

COVID-19 case fatality and Parkinson's disease.
Zhang Q, Schultz JL, Aldridge GM, Simmering JE, Narayanan NS.Zhang Q, et al. Mov Disord. 2020 Sep 21. doi: 10.1002/mds.28325. Online ahead of print.

  Myoclonus in COVID Patients

Myoclonus and COVID-19: A Challenge for the Present, a Lesson for the Future.
Latorre A, Rothwell JC.

Myoclonus in Patients With Coronavirus Disease 2019: A Multicenter Case Series.
Anand P, Zakaria A, Benameur K, Ong C, Putman M, O'Shea S, Greer D, Cervantes-Arslanian AM

Reversible Myoclonus-Ataxia as a Postinfectious Manifestation of COVID-19.
Schellekens MMI, Bleeker-Rovers CP, Keurlings PAJ, Mummery CJ, Bloem BR.

Subcortical myoclonus in COVID-19: comprehensive evaluation of a patient.
Muccioli L, Rondelli F, Ferri L, Rossini G, Cortelli P, Guarino M

Diaphragmatic myoclonus due to SARS-CoV-2 infection.
Borroni B, Gazzina S, Dono F, Mazzoleni V, Liberini P, Carrarini C, Russo M, Pontolillo M, Vecchiet J, Onofrj M, Bonanni L.

Post-hypoxic myoclonus after COVID-19 infection recovery.
Ros-Castelló V, Quereda C, López-Sendón J, Corral I.

Opsoclonus myoclonus ataxia syndrome (OMAS) in the setting of COVID-19 infection.
Shah PB, Desai SD

Opsoclonus Myoclonus Ataxia Syndrome Related to the Novel Coronavirus (COVID-19).
Sanguinetti S, Ramdhani RA.

Myoclonus and cerebellar ataxia following Coronavirus Disease 2019 (COVID-19).
Dijkstra F, Van den Bossche T, Willekens B, Cras P, Crosiers D.

Generalized myoclonus in COVID-19.
Rábano-Suárez P, Bermejo-Guerrero L, Méndez-Guerrero A, Parra-Serrano J, Toledo-Alfocea D, Sánchez-Tejerina D, Santos-Fernández T, Folgueira-López MD, Gutiérrez-Gutiérrez J, Ayuso-García B, González de la Aleja J, Benito-León J.

Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature.
Emamikhah M, Babadi M, Mehrabani M, Jalili M, Pouranian M, Daraie P, Mohaghegh F, Aghavali S, Zaribafian M, Rohani M. J Neurovirol. 2021 Jan 25:1-9

  Psychological / Psychiatric Issues in Movement Disorder Patients in the Era of COVID-19

Higher perceived stress and exacerbated motor symptoms in Parkinson's disease during the COVID-19 lockdown in New Zealand.
Blakemore RL, Pascoe MJ, Horne KL, Livingston L, Young BN, Elias B, Goulden M, Grenfell S, Myall DJ, Pitcher TL, Dalrymple-Alford JC, Le Heron CJ, Anderson TJ, MacAskill MR. N Z Med J. 2021 Jul 9;134(1538):44-51.

The psychological impact of COVID-19 among a sample of Italian patients with functional neurological disorders: A preliminary study.
Nisticò V, Goeta D, Gambini O, Demartini B.

COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications.
Yamamoto V, Bolanos JF, Fiallos J, Strand SE, Morris K, Shahrokhinia S, Cushing TR, Hopp L, Tiwari A, Hariri R, Sokolov R, Wheeler C, Kaushik A, Elsayegh A, Eliashiv D, Hedrick R, Jafari B, Johnson JP, Khorsandi M, Gonzalez N, Balakhani G, Lahiri S, Ghavidel K, Amaya M, Kloor H, Hussain N, Huang E, Cormier J, Wesson Ashford J, Wang JC, Yaghobian S, Khorrami P, Shamloo B, Moon C, Shadi P, Kateb B. J Alzheimers Dis. 2020;77(2):459-504. doi: 10.3233/JAD-200831.

Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID-19) Pandemic.
Salari M, Zali A, Ashrafi F, Etemadifar M, Sharma S, Hajizadeh N, Ashourizadeh H. Mov Disord. 2020 May

Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life
Subramanian I, Farahnik J, Mischley LK.

Changes in Motor, Cognitive, and Behavioral Symptoms in Parkinson's Disease and Mild Cognitive Impairment During the COVID-19 Lockdown.

Baschi R, Luca A, Nicoletti A, Caccamo M, Cicero CE, D'Agate C, Di Giorgi L, La Bianca G, Lo Castro T, Zappia M, Monastero R. Front Psychiatry. 2020 Dec 14;11:590134. doi: 10.3389/fpsyt.2020.590134. eCollection 2020.

  Management of PD in the Time of COVID

The Challenge of Managing Parkinson's Disease Patients during the COVID-19 Pandemic.
Garg D, Dhamija RK. Ann Indian Acad Neurol. 2020 Apr;23(Suppl 1):S24-S27.

Management of a Parkinson's disease patient with severe COVID-19 pneumonia.
Li J, Long X, Zhu C, Wang R, Hu S, Wang T, Li J, Lin Z, Xiong N.Li J, et al. Ther Adv Chronic Dis. 2020 Aug 11;11:2040622320949423

The impact of COVID-19 on access to Parkinson's disease medication.
Cheong JLY, Goh ZHK, Marras C, Tanner CM, Kasten M, Noyce AJ; Movement Disorders Society Epidemiology Study Group.Cheong JLY, et al. Mov Disord. 2020 Aug 28

Physical activity changes and correlate effects in patients with Parkinson's disease during COVID-19 lockdown.
Schirinzi T, Di Lazzaro G, Salimei C, Cerroni R, Liguori C, Scalise S, Alwardat M, Mercuri NB, Pierantozzi M, Stefani A, Pisani A.Schirinzi T, et al. Mov Disord Clin Pract. 2020 Jul 17

Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID-19 Pandemic.
Shalash A, Roushdy T, Essam M, Fathy M, Dawood NL, Abushady EM, Elrassas H, Helmi A, Hamid E. Mov Disord. 2020 May 19:

Hoping for the best, planning for the worst: Palliative care approach to Parkinson disease during the COVID-19 pandemic.
Indu Subramanian, Christina L Vaughan.Indu Subramanian, et al. Parkinsonism Relat Disord. 2020 Oct 6:S1353-8020(20)30774-4. doi: 10.1016/j.parkreldis.2020.09.042. Online ahead of print.

Novel Outreach Program and Practical Strategies for Patients with Parkinsonism in the COVID-19 Pandemic.
Sennott B, Woo K, Hess S, Mitchem D, Klostermann EC, Myrick E, Savica R, Fleisher JE.Sennott B, et al. J Parkinsons Dis. 2020 Aug 6

Potential impact and challenges associated with Parkinson's disease patient care amidst the COVID-19 global pandemic.
Elbeddini A, To A, Tayefehchamani Y, Wen C.Elbeddini A, et al. J Clin Mov Disord. 2020 Aug 8;7:7.

Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy.
Schirinzi T, Cerroni R, Di Lazzaro G, Liguori C, Scalise S, Bovenzi R, Conti M, Garasto E, Mercuri NB, Pierantozzi M, Pisani A, Stefani A. Neurol Sci. 2020 Jun;41(6):1373-1375.

Parkinson's disease after COVID-19.
Makhoul K, Jankovic J. J Neurol Sci. 2021 Jan 28;422:117331.

  COVID-19 and Deep Brain Stimulation

Recommendations for Deep Brain Stimulation Device Management During a Pandemic.
Miocinovic S, Ostrem JL, Okun MS, Bullinger KL, Riva-Posse P, Gross RE, Buetefisch CM. J Parkinsons Dis. 2020 Apr 24.

Strategies to mitigate impacts of the COVID-19 pandemic on patients treated with deep brain stimulation.
Kostick K, Storch EA, Zuk P, Blumenthal-Barby JS, Torgerson L, Yoshor D, Sheth S, Viswanathan A, Tarakad A, Jimenez-Shahed J, Goodman W, Lázaro-Muñoz G.Kostick K, et al. Brain Stimul. 2020 Oct 2;13(6):1642-1643.

  Technical Solutions, Virtual Consultation

Telemedicine in Parkinson's Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic. Miele G, Straccia G, Moccia M, Leocani L, Tedeschi G, Bonavita S, Lavorgna L; Digital Technologies, Web and Social Media Study Group of the Italian Society of Neurology.Miele G, et al. Telemed J E Health. 2020 Jul 13

Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson's Disease During the COVID-19 Pandemic: New Expectations for the Future.
Cubo E, Hassan A, Bloem BR, Mari Z; MDS-Telemedicine Study Group. J Parkinsons Dis. 2020 May 12

Parkinson's Disease Remote Patient Monitoring During the COVID-19 Lockdown.
Motolese F, Magliozzi A, Puttini F, Rossi M, Capone F, Karlinski K, Stark-Inbar A, Yekutieli Z, Di Lazzaro V, Marano M

Remote Administration of the MDS-UPDRS in the Time of COVID-19 and Beyond.
Schneider RB, Myers TL, Tarolli CG, Amodeo K, Adams JL, Jensen-Roberts S, Dorsey ER.Schneider RB, et al. J Parkinsons Dis. 2020 Jul 15.

Promoting Physical Activity via Telehealth in People With Parkinson Disease: The Path Forward After the COVID-19 Pandemic?
Quinn L, Macpherson C, Long K, Shah H.

Virtual Parkinson's Disease Support Groups in the COVID-19 Era: Social Connection in the Time of Social Distancing.
Subramanian I.Subramanian I. Mov Disord Clin Pract. 2020 Jul 10;7(6):739-740

Global survey on telemedicine utilization for movement disorders during the COVID-19 pandemic.
Hassan A, Mari Z, Gatto EM, Cardozo A, Youn J, Okubadejo N, Bajwa JA, Shalash A, Fujioka S, Aldaajani Z, Cubo E; International Telemedicine Study Group.Hassan A, et al. Mov Disord. 2020 Aug 24.

E-Rehabilitation: One solution for patients with Parkinson's disease in COVID-19 era.
Srivastav AK, Samuel AJ.Srivastav AK, et al. Parkinsonism Relat Disord. 2020 Jun 4:S1353-8020(20)30130-9.

Global Perspective on Telemedicine for Parkinson's Disease.
Shalash A, Spindler M, Cubo E. J Parkinsons Dis. 2021 Feb 8.

  COVID-19 and Other Movement Disorders

Functional movement disorders in a patient with COVID-19.
Piscitelli D, Perin C, Tremolizzo L, Peroni F, Cerri CG, Cornaggia CM.Piscitelli D, et al. Neurol Sci. 2020 Jul 14:1-2.

  Other Publications

Basal Ganglia Involvement and Altered Mental Status: A Unique Neurological Manifestation of Coronavirus Disease 2019.
Haddadi K, Ghasemian R, Shafizad M. Cureus. 2020 Apr 28;12(4):e7869.

Knowledge, Attitudes, Practices, and Burden During the COVID-19 Pandemic in People with Parkinson's Disease in Germany. Zipprich HM, Teschner U, Witte OW, Schönenberg A, Prell T. J Clin Med. 2020 May 29;9(6):E1643

Unmet Needs of People With Parkinson's Disease and Their Caregivers During COVID-19-Related Confinement: An Explorative Secondary Data Analysis.
Hanff AM, Pauly C, Pauly L, Schröder VE, Hansen M, Meyers GR, Kaysen A, Hansen L, Wauters F, Krüger R. Front Neurol. 2021 Jan 18;11:615172

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice